Filing Flows › Neurocrine Biosciences (NBIX) › Net income
Neurocrine Biosciences (NBIX) net income by quarter
Neurocrine Biosciences' net income was $206M in Q3 2026 (third quarter 2026), +43% from Q2 2026. Over the last 7 quarters it ranged from $7.9M (Q1 2025) to $210M (Q3 2025).
| Quarter | Net income | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $206M | +43% | -1% |
| Q2 2026 | $144M | -27% | +34% |
| Q1 2026 | $198M | +29% | 25× |
| Q4 2025 | $154M | -27% | — |
| Q3 2025 | $210M | +95% | — |
| Q2 2025 | $108M | 14× | — |
| Q1 2025 | $7.9M | — | — |
Q3 2026 at a glance
Neurocrine Biosciences, Q3 2026: revenue $1.1B (+41% year over year), operating margin 29.5%, net earnings $206M, operating cash flow $395M. The chart follows the revenue to costs, profit and cash.
Questions
What is Neurocrine Biosciences' net income?
Neurocrine Biosciences' net income was $206M in Q3 2026 (third quarter 2026), +43% from Q2 2026.
How has Neurocrine Biosciences' net income changed?
Over the last 7 quarters it ranged from $7.9M (Q1 2025) to $210M (Q3 2025).
Q3 2026 results → · How Neurocrine Biosciences makes money →